Pharmaceuticals - Indian - Bulk Drugs
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 2,532.61 | 2,718.25 | 2,499.96 | 2,159.30 | 1,807.57 |
Total Expenses | 2,297.08 | 2,494.07 | 2,230.01 | 1,790.52 | 1,626.75 |
Profit Before Tax | 235.53 | 224.18 | 269.96 | 369.01 | 185.29 |
Profit After Tax | 171.59 | 166.36 | 205 | 280.40 | 141.40 |
Operating Profit after Depreciation | 269.04 | 257.48 | 290.70 | 391.75 | 214.55 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 846.73 | 699.77 | 689.93 | 665.40 | 643.81 |
Total Non Current Assets | 1,111.64 | 929.61 | 814.59 | 709.22 | 677.05 |
Total Current Assets | 1,320.72 | 1,491.79 | 1,393.37 | 1,056.80 | 899.45 |
TOTAL ASSETS | 2,432.36 | 2,421.40 | 2,207.96 | 1,766.01 | 1,576.50 |
Total Shareholder's Fund | 1,281.55 | 1,192.43 | 1,036.36 | 913.42 | 652.49 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 358.92 | 133.32 | 70.41 | 154.95 | 250.74 |
Net Cash used in Investing Activities | -223.65 | -163.97 | -149.64 | -71.78 | -33.21 |
Net Cash used in Financing Activities | -136.03 | 16.54 | 92.03 | -81.13 | -215.41 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 2,271.09 | 2,500.20 | 2,255.95 | 1,921.31 | 1,635.98 |
Total Expenses | 2,078.61 | 2,295.39 | 2,000.45 | 1,583.83 | 1,469.39 |
Profit Before Tax | 192.48 | 204.81 | 255.50 | 337.71 | 174.97 |
Profit After Tax | 141.88 | 152.81 | 195 | 257.71 | 135.67 |
Operating Profit after Depreciation | 222.64 | 237.34 | 275.56 | 360.10 | 198.80 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 722.29 | 634.48 | 649.41 | 630.52 | 611.57 |
Total Non Current Assets | 990.60 | 845.96 | 761.33 | 676.88 | 645.33 |
Total Current Assets | 1,181.02 | 1,349.53 | 1,273.19 | 960.13 | 825.36 |
TOTAL ASSETS | 2,171.62 | 2,195.50 | 2,034.52 | 1,637.01 | 1,470.70 |
Total Shareholder's Fund | 1,175.21 | 1,114.30 | 972.17 | 859.61 | 621.79 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 337.10 | 161.70 | 39.90 | 154.18 | 196.15 |
Net Cash used in Investing Activities | -187.09 | -131.14 | -125.36 | -69.03 | -29.35 |
Net Cash used in Financing Activities | -148.81 | -30.54 | 84.11 | -85.28 | -167.76 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 556.60 | 598.33 | 555.34 | 619.99 | 605.94 |
Total Expenses | 494.88 | 531.28 | 490.38 | 534.18 | 535.80 |
Profit Before Tax | 50.75 | 45.88 | 43.98 | 64.18 | 51.55 |
Profit After Tax | 37.09 | 34.96 | 33.27 | 47.31 | 36.71 |
Operating Profit after Depreciation | 73.62 | 68.53 | 66.07 | 86.89 | 71.81 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 514.54 | 543.09 | 492.96 | 559.53 | 538.21 |
Total Expenses | 454.29 | 483.55 | 438.73 | 490.47 | 478.47 |
Profit Before Tax | 52.03 | 40.89 | 35.16 | 49.74 | 42.87 |
Profit After Tax | 38.53 | 30.39 | 26.91 | 36.14 | 31.62 |
Operating Profit after Depreciation | 71.62 | 59.92 | 54.33 | 70.17 | 61.42 |
₹1/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Aarti Drugs Ltd | ₹407.65 | ₹3,747.73 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
30 Jan 2025, 12:14 pm
29 Jan 2025, 05:03 pm
23 Jan 2025, 11:25 am
24 Dec 2024, 03:48 pm
24 Dec 2024, 03:12 pm